Form 8-K - Current report:
SEC Accession No. 0001628280-19-014834
Filing Date
2019-12-06
Accepted
2019-12-06 17:17:42
Documents
3
Period of Report
2019-12-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K a8kreditrexapproval12-6x19.htm 8-K 37213
2 EXHIBIT 99.1 methotrexateapprovalfinal.htm EX-99.1 21955
3 methotrexateapprovalf_image1.jpg GRAPHIC 37721
  Complete submission text file 0001628280-19-014834.txt   112290
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 191273821
SIC: 2834 Pharmaceutical Preparations